AOC 1001

DB18620InvestigationalProtein Based Therapies

Delpacibart (AOC 1001) is being investigated in a global study for the treatment of Myotonic Dystrophy type 1 (DM1) in clinical trial NCT06411288.

Mechanism
Curator reviewed
Also known as
Delpacibart · Immunoglobulin G1 [233-alanine,234-alanine,327-arginine,de-446-lysine], anti-(human type 1 transferrin receptor) (human-Mus musculus clone AV05 γ1-chain), disulfide with human-Mus musculus clone AV05 κ-chain, dimer
Code names
AOC-1001

Resolves to

Compound
UNII9Q5NSR8WV9CAS2653183-66-3
Targets
Q09013DMPK

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with AOC 1001, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In